FDA approves Otsuka’s ADHD drug Simtriyo, teeing up its ‘next major CNS launch’

Otsuka Pharmaceutical stands to capture a sizable slice of the ADHD market as its newly approved drug Simtriyo opens a fresh therapeutic class, creating a potential revenue boost and attracting investor interest. Competitors that currently sell stimulant or non‑stimulant ADHD medicines, including those behind Qelbree, may face heightened competition for prescribers and reimbursement dollars. Payers could also reassess formulary placements in light of a novel mechanism of action.

Food and Drug Administration granted approval for Simtriyo, designating it the first triple‑reuptake inhibitor authorized for ADHD treatment. MedPage Today emphasized that Simtriyo represents a first‑in‑class option distinct from traditional stimulants. Fierce Pharma added that the approval sets the stage for Otsuka’s next major central‑nervous‑system launch.

BioSpace estimated a $615 million opportunity for the new drug class, reflecting early market expectations based on pricing assumptions and patient volume. BioWorld News examined how Simtriyo’s arrival will be weighed against existing options such as Qelbree in prescribing decisions. With regulatory clearance secured, Otsuka can begin commercial rollout, engage insurers for coverage agreements, and move forward with pipeline candidates aimed at other central‑nervous‑system disorders.